Thu, December 20, 2012
[ Thu, Dec 20th 2012 ] - Market Wire
A View from the Top
Wed, December 19, 2012
Tue, December 18, 2012
Mon, December 17, 2012
Fri, December 14, 2012
Thu, December 13, 2012
Wed, December 12, 2012
Tue, December 11, 2012
Mon, December 10, 2012
Sun, December 9, 2012
Sat, December 8, 2012
Fri, December 7, 2012
Thu, December 6, 2012
Wed, December 5, 2012
Tue, December 4, 2012
Mon, December 3, 2012
Sun, December 2, 2012
Sat, December 1, 2012
Fri, November 30, 2012
Thu, November 29, 2012
Wed, November 28, 2012
Tue, November 27, 2012

Threshold Pharmaceuticals Announces Presentation and Webcast at Oppenheimer 23rd Annual Healthcare Conference


//health-fitness.news-articles.net/content/2012/ .. penheimer-23rd-annual-healthcare-conference.html
Published in Health and Fitness on Monday, December 10th 2012 at 4:46 GMT by Market Wire   Print publication without navigation


December 10, 2012 07:30 ET

Threshold Pharmaceuticals Announces Presentation and Webcast at Oppenheimer 23rd Annual Healthcare Conference

SOUTH SAN FRANCISCO, CA--(Marketwire - Dec 10, 2012) - Threshold Pharmaceuticals, Inc. (NASDAQ: [ THLD ]) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Oppenheimer 23rd Annual Healthcare Conference at 3:20 p.m. ET on Thursday, December 13, 2012.

A live webcast of the presentation will be available under Webcasts in the Investors section of [ www.thresholdpharm.com ]. A replay of the presentation will be archived on the site for 30 days.

About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website ([ www.thresholdpharm.com ]).

Forward-Looking Statements
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding the potential therapeutic uses and benefits of its product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to enroll or complete its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission on November 2, 2012 and is available from the SEC's website ([ www.sec.gov ]) and on our website ([ www.thresholdpharm.com ]) under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.



Publication Contributing Sources